Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who purchased Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [4] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [5] Product Development and Regulatory Issues - Defendants had previously indicated that they expected the FDA to grant accelerated approval for INO-3107 and aimed to complete the rolling submission of its Biologics License Application (BLA) by the second half of 2024 [5] - However, it was later revealed that manufacturing issues with the CELLECTRA device would delay the BLA submission to mid-2025, representing a full-year delay from the initial timeline [8] Stock Performance and Market Reaction - Following the announcement of the delay in BLA submission on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share [9] - On December 29, 2025, the FDA accepted the INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a significant drop in stock price by $0.56 per share, or 24.45%, closing at $1.73 per share [10][11] Misleading Statements - Throughout the Class Period, Defendants allegedly made materially false and misleading statements regarding the company's operations and prospects, including deficiencies in manufacturing and overstated regulatory and commercial prospects for INO-3107 [7]

Inovio Pharmaceuticals Conference Call Summary Company Overview - Inovio Pharmaceuticals is a clinical-stage biotech company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2][3] - The company has submitted a Biologics License Application (BLA) for its lead program, INO-3107, which targets Recurrent Respiratory Papillomatosis (RRP) caused by HPV types 6 and 11 [2][3] Regulatory Status - The BLA for INO-3107 has been accepted for review by the FDA under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026 [3] - Inovio has received Orphan Drug and Breakthrough Therapy designations for INO-3107 [3] - The company is preparing to address preliminary comments from the FDA regarding eligibility for the Accelerated Approval Program [3][27] Product Details - INO-3107 is a combination product that includes a DNA medicine and a delivery device [3] - The treatment aims to generate an antigen-specific T-cell response against HPV6 and HPV11, addressing the underlying cause of RRP rather than just managing symptoms through surgery [9][10] - Epidemiology suggests approximately 14,000 active RRP cases in the U.S., with an incidence rate of 1.8 per 100,000 annually [7] Clinical Data - Efficacy data shows that 72% of patients experienced a 50%-100% reduction in surgeries in the first year, improving to 86% in the second year [11] - Complete response rates were 28% in year one and 50% in year two, indicating a significant reduction in the need for surgeries [11] - The treatment was well tolerated, with common adverse events being transient injection site pain (30% of participants) and fatigue, but no discontinuations were reported [12] Competitive Landscape - Inovio believes it has a preferred product profile compared to existing treatments, particularly due to its improved safety profile and the ability to administer the treatment in a doctor's office without the need for surgeries [29][45] - The approved product requires scoping and surgeries, which adds logistical burdens and risks for patients [45][63] Manufacturing and Commercialization - INO-3107 is manufactured at FDA-approved contract manufacturers, with the drug substance produced by one manufacturer and the final product filled by another [51] - The company is preparing for commercial launch, including market research and establishing distribution channels [58][61] Future Pipeline - Following INO-3107, Inovio has other candidates in development, including INO-5401 and INO-3112, which are T-cell based therapies [13][14] - The company is also exploring next-generation therapeutics for protein replacement diseases [14] Regulatory Feedback - Inovio has received differing feedback from European regulators, who are looking for placebo-controlled data and data from two efficacy trials, contrasting with the FDA's approach [39][41] Investor Insights - Inovio emphasizes the potential of its T-cell technology and the exciting prospects of its dMAb and dProt programs, which are gaining interest from potential partners [64][66]

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit due to alleged securities fraud, with a deadline for shareholders to file a lead plaintiff motion by April 7, 2026. The lawsuit claims that the company made misleading statements regarding its product development and regulatory prospects, leading to significant stock price declines [1]. Summary by Relevant Sections Company Performance - Inovio's stock price fell by $0.27 (3.1%) to close at $8.44 per share on August 9, 2024, following the announcement of a delay in submitting the Biologics License Application (BLA) for INO-3107 due to manufacturing issues [1]. - On December 29, 2025, the stock price dropped by $0.56 (24.45%) to close at $1.73 per share after the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review [1]. Legal Proceedings - The class action lawsuit alleges that Inovio's management made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects during the class period from October 10, 2023, to December 26, 2025 [1]. - Specific allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device, the unlikelihood of timely BLA submission, and overstated regulatory and commercial prospects for INO-3107 [1]. Investor Actions - Shareholders who suffered losses during the class period are encouraged to contact Glancy Prongay Wolke & Rotter LLP to potentially pursue claims under federal securities laws [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1]. Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [4]. - The company's DNA medicines consist of DNA plasmids and a proprietary device called "CELLECTRA," which aids in delivering these medicines into cells [4]. Product Candidate - Inovio's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [5]. - The company has indicated expectations for FDA accelerated approval and a rolling submission of the Biologics License Application (BLA) for INO-3107 by the second half of 2024, which is critical for its transition into a commercial-stage company [5]. Allegations of Misleading Statements - Throughout the Class Period, Inovio's executives allegedly made materially false and misleading statements regarding the company's operations and prospects, including deficiencies in manufacturing the CELLECTRA device and overstated regulatory and commercial prospects for INO-3107 [7]. - The company reportedly conducted multiple securities offerings during this period, generating tens of millions of dollars while disseminating positive statements about its prospects [6]. Emergence of Truth - The truth began to surface on August 8, 2024, when Inovio announced a delay in the submission of the INO-3107 BLA to mid-2025 due to manufacturing issues, resulting in a 3.1% drop in stock price [8][9]. - On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA for standard review rather than accelerated review, leading to a significant stock price decline of 24.45% [10][11].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged securities fraud, impacting investors who purchased shares between October 10, 2023, and December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Inovio made materially false and misleading statements regarding its business operations and prospects during the class period [1]. - Investors have until April 7, 2026, to file a lead plaintiff motion in the ongoing lawsuit [1]. - The complaint alleges that Inovio failed to disclose significant issues related to its CELLECTRA device manufacturing and the likelihood of timely FDA submission for its INO-3107 treatment [1]. Group 2: Stock Price Impact - Following the announcement of a delay in the BLA submission for INO-3107 due to manufacturing issues, Inovio's stock price fell by $0.27, or 3.1%, closing at $8.44 on August 9, 2024 [1]. - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56, or 24.45%, closing at $1.73 [1]. Group 3: Allegations of Misleading Information - The lawsuit alleges that Inovio overstated the regulatory and commercial prospects of INO-3107, leading to materially misleading statements about the company's business [1]. - Specific allegations include deficiencies in manufacturing for the CELLECTRA device and insufficient information to justify eligibility for FDA accelerated approval [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]

Core Viewpoint - INOVIO's Biologics License Application (BLA) for INO-3107 has been accepted by the FDA for review as a potential treatment for adults with recurrent respiratory papillomatosis (RRP), with a standard review classification assigned [1][2] Group 1: FDA Review Process - The FDA has set a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, for INO-3107, indicating when it intends to take action on the application [2] - INOVIO filed the BLA under the accelerated approval pathway, although the FDA has raised concerns about the adequacy of information submitted for this pathway [3] Group 2: Clinical Data and Efficacy - INO-3107 has shown potential therapeutic benefits in clinical trials, with 72% of patients experiencing a 50-to-100% reduction in surgeries after one year of treatment, increasing to 86% in the second year without additional dosing [6][4] - The BLA is supported by data from a Phase 1/2 trial involving adult patients with RRP who had undergone multiple surgeries prior to treatment, demonstrating long-term clinical benefits [4][6] Group 3: Disease Background and Market Need - RRP is a rare disease primarily caused by HPV-6 and HPV-11, leading to the development of benign papillomas in the respiratory tract, which can cause severe complications [5] - Current standard care involves surgical removal of papillomas, but they often regrow, highlighting the need for effective non-surgical treatment options [5] Group 4: INO-3107 and its Mechanism - INO-3107 is designed to elicit a T cell response against HPV-6 and HPV-11, potentially preventing or slowing the growth of new papillomas [6][7] - The treatment has shown a strong immune response and was well tolerated in clinical trials, with mostly low-grade adverse effects reported [6][7] Group 5: Regulatory Designations and Market Access - INO-3107 has received Orphan Drug and Breakthrough Therapy designations from the FDA, as well as Orphan Drug designation from the European Commission [8] - The CELLECTRA delivery device has been CE-marked in the EU, allowing for commercialization in regions recognizing this certification [8]

Core Insights - INOVIO has completed the rolling submission of its Biologics License Application (BLA) for its DNA immunotherapy candidate INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP) in adults [1][2] - The BLA was submitted under the FDA's Accelerated Approval program, with a request for priority review, which could lead to a decision within six months [2][4] - If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the United States [2] Company Overview - INOVIO is a biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [8] - The company utilizes a proprietary DNA medicines platform that includes precisely designed DNA plasmids delivered by its investigational medical device, CELLECTRA [7] Product Details - INO-3107 is designed to elicit an antigen-specific T cell response against HPV-6 and HPV-11 proteins, potentially preventing or slowing the growth of new papillomas [3][4] - In a Phase 1/2 trial, 72% of participants experienced a 50-to-100% reduction in the number of surgeries required after one year of treatment, with this number increasing to 86% after two years [3][4] Market Context - RRP is a rare disease primarily caused by HPV-6 and HPV-11, characterized by wart-like growths in the respiratory tract, which can lead to severe complications [3][4] - The standard treatment involves surgery to remove papillomas, but they often regrow, highlighting the need for effective alternative therapies [3][4] Regulatory Status - INO-3107 has received Orphan Drug and Breakthrough Therapy designations from the FDA, facilitating its expedited review process [4][6] - The company anticipates receiving file acceptance by the end of 2025, with a potential Prescription Drug User Fee Act (PDUFA) date in mid-2026 if priority review is granted [4][6]